Kuznicki Law is investigating the proposed sale of Decibel Therapeutics, Inc. (NasdaqGS: DBTX) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN). Under the terms of the proposed transaction, shareholders of Decibel will receive only $4.00 in cash for each share of Decibel that they own, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the merger is structured as a tender offer, such that time may be of the essence.